



MEDIA RELEASE

Significant shareholder places shares with institutional investors

Glattpark (Opfikon), 30 August 2023 – Implenia has been informed that UBS AG, on behalf of Norbert Ketterer, placed a total of 1,295,688 Implenia Ltd. shares, corresponding to about 7% of the share capital, with institutional investors in an accelerated bookbuilding process after yesterday's close of trading.

According to the latest notification to Implenia and SIX Swiss Exchange, Norbert Ketterer held 1,848,000 registered Implenia shares on 3 March 2020, corresponding to 10.004% of the share capital and voting rights.

Contact for media:

Corporate Communications, T +41 58 474 74 77, communication@implenia.com

Contact for Investors and Analysts:

Investor Relations, T +41 58 474 35 04, ir@implenia.com

Dates for investors:

28 February 2024: Annual results 2023, Analysts and Media Conference

26 March 2024: Annual General Meeting

As Switzerland's leading construction and real estate service provider, Implenia develops, builds and manages homes, workplaces and infrastructure for future generations in Switzerland and Germany. It also offers tunnelling and related infrastructure projects in further markets. Formed in 2006, the company can look back on around 150 years of construction tradition. The company brings together the know-how of its highly skilled development, planning and execution units under the umbrella of an integrated leading multinational construction and real estate service provider. With its broad offering and the expertise of its specialists, the Group realises large, complex projects and provides client-centric support across the entire life cycle of a building or structure. It focuses on client needs and on striking a sustainable balance between commercial success and social and environmental responsibility. Implenia, with its headquarters in Opfikon near Zurich, has more than 9,000 employees (FTE) across Europe and posted revenue of CHF 3.6 billion in 2022. The company is listed on the SIX Swiss Exchange (IMPN, CH0023868554). More information can be found at implenia.com.